The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

2 Jan 2020 15:28

RNS Number : 6010Y
e-Therapeutics plc
02 January 2020
 

E-THERAPEUTICS PLC

 

("e-therapeutics" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES AND ISSUE OF EQUITY

 

Oxford, UK, 2 January 2020 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that on 2 January 2020 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 177,404 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") at a price of 3.10 pence per share. The subscription monies paid for the New Ordinary Shares represent 50% of Professor Jones' Non-Executive Director fees net of tax paid during the period from 1 July 2019 to 31 December 2019 in accordance with the agreement entered into with Professor Jones, previously announced on 5 October 2016, by which Professor Jones agreed, with effect from 1 October 2016, to invest 50% of his annual Non-Executive Director fees net of tax in new e-therapeutics' ordinary shares. Such new shares are issued to Professor Jones on the first business day after 31 December and 30 June in each year. The subscription price to be paid is the average of the closing mid-market price for the five business days prior to the date of issue.

 

Following Admission, Professor Jones will be interested in a total of 916,353 ordinary shares of 0.1p in the Company, representing approximately 0.34% of the Company's issued share capital.

 

Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on 10 January 2020. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

 

Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 269,125,498. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Trevor Jones

2

Reason for the notification

a)

Position/status 

Non-Executive Director

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

e-therapeutics plc 

b)

LEI

21380049RHSSJXWKYT18

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 0.1 pence

 

ISIN: GB00B2823H99

b)

Nature of the transaction

Purchase of shares 

c)

Price(s) and volume(s)

177,404 ordinary shares at a price of 3.10 pence per share

d)

Aggregated information

- Aggregated volume

- Price

 

177,404 ordinary shares

3.10 pence per share

Aggregated value: £5,499.54

e)

Date of the transaction

2 January 2020

 

f)

Place of the transaction

Outside a trading venue

 

For further information, please contact:

 

 

e-therapeutics plc

Ray Barlow, Chief Executive Officer

Steve Medlicott, Chief Financial Officer

 

Tel: +44 (0) 1993 883 125

www.etherapeutics.co.uk 

 

Numis Securities Limited

Freddie Barnfield/Duncan Monteith(Nominated Adviser)

James Black (Corporate Broking)

 

Tel: +44 (0) 207 260 1000

www.numis.com

 

FTI Consulting

Simon Conway

Tel: +44 (0) 203 727 1000

Email: etherapeutics@fticonsulting.com

 

 

About e-therapeutics

 

e-therapeutics is an Oxford, UK-based company with a unique and powerful computer-based approach to drug discovery, founded on our industry-leading expertise in network biology.

 

We have created two proprietary, unique and productive technology platforms. The first is our proprietary Network-Driven Drug Discovery ("NDD") platform, which is based on sophisticated network science and employs techniques such as machine learning, artificial intelligence ("AI") and state-of-the-art data analysis tools. NDD allows the more efficient discovery of new and better drugs and has been validated in multiple and diverse areas of biology.

 

The second is our Genome Associated Network Interactions ("GAINs") platform. GAINs is a revolutionary and entirely novel approach to functional genomics, based on the same validated network biology and analytics expertise that underpins our NDD technologies. GAINs analyses human genetic data to allow a deep and valuable understanding about the mechanisms that cause disease. GAINs has the potential to uncover unrecognised disease processes and pathways and can enable the discovery of novel drugs, diagnostics and biomarkers in a way not previously possible from population genomics data, such as genome-wide association studies ("GWAS").

 

We use our highly productive drug discovery engine to develop our own IP-protected, pre-clinical drug discovery programmes, particularly appealing to partners looking to acquire or in-license novel and differentiated assets. We are currently developing two programmes in immuno-oncology in-house and have a number of partner-ready projects in areas including fibrosis and the tumour microenvironment.

 

We have partnerships with Novo Nordisk in Type-2 diabetes and a US-based, top 5 pharmaceutical company in neurodegeneration. We are working on different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFLFFELRIFIII
Date   Source Headline
24th May 20116:30 pmRNSDirector/PDMR Shareholding
23rd May 20115:59 pmRNSDirector/PDMR Shareholding
15th Mar 20112:47 pmRNSDirector/PDMR Shareholding
15th Mar 201110:35 amRNSHolding(s) in Company
14th Mar 201112:00 pmRNSDirector/PDMR Shareholding
10th Mar 201111:07 amRNSRe-statement of Directors' Interests
10th Mar 201110:20 amRNSHolding(s) in Company
8th Mar 20116:11 pmRNSHolding(s) in Company
8th Mar 20116:01 pmRNSHolding(s) in Company
7th Mar 20118:22 amRNSCompletion of the Placings
4th Mar 20119:13 amRNSDirector/PDMR Shareholding
3rd Mar 20112:08 pmRNSResult of General Meeting
2nd Mar 20119:28 amRNSDirector/PDMR Shareholding
15th Feb 20117:30 amRNSIssue of Equity
3rd Feb 201112:09 pmRNSIssue of Equity
6th Dec 20107:00 amRNSDirectorate Change
29th Oct 20107:00 amRNSe-Therapeutics plc Interim Results
22nd Sep 20107:00 amRNSComprehensive Set of Patents Granted in US
8th Sep 201010:24 amRNSAGM Statement
30th Jul 20108:00 amRNSAnnual Financial Report
29th Jul 201010:23 amRNSAdditional Listing
2nd Jul 20108:00 amRNSDirectors' Interests
29th Jun 20107:00 amRNSFinal Results
25th May 20107:30 amRNSChange of Adviser
29th Apr 20109:02 amRNSIssue of Equity
29th Apr 20107:00 amRNSPre-close operational update and notice of Results
10th Mar 20104:01 pmRNSDirector's interest
2nd Mar 20109:30 amRNSDirector's shareholdings
15th Feb 20107:00 amRNSContract for iGCP trials with Infinitus
11th Nov 20095:46 pmRNSHolding(s) in Company
2nd Nov 200912:00 pmRNSPlacing
30th Oct 20097:00 amRNSInterim results
2nd Sep 200910:05 amRNSResult of AGM
11th Aug 20097:00 amRNSNotice of AGM
27th Jul 20097:42 amRNSPreliminary Results
14th Jul 20097:00 amRNSNotice of Results
25th Jun 20091:00 pmRNSChange of Adviser
17th Jun 20094:05 pmRNSDirector/PDMR Shareholding
9th Jun 200911:36 amRNSDirector Declaration
16th Mar 20094:34 pmRNSResult of General Meeting
11th Mar 20092:19 pmRNSDirector/PDMR Shareholding
25th Feb 20093:00 pmRNSNotice of General Meeting
25th Feb 20097:00 amRNSConditional Investment & Notice of General Meeting
24th Feb 20097:00 amRNSRevenue share agreement with Khandelwal
26th Jan 20097:00 amRNSStrategic Partnership
14th Jan 20097:00 amRNSPositive Phase IIa results for antidepressant
12th Jan 20091:23 pmRNSUS patent granted
12th Nov 20085:04 pmRNSShare Option Award
11th Nov 20083:02 pmRNSGrant of patents
31st Oct 20087:00 amRNSDirector's Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.